Gilead Sciences has announced a definitive agreement to acquire Ouro Medicines in a deal valued at over USD 2 billion, marking a strategic move to expand its immunology and inflammation pipeline.

The transaction includes an upfront cash payment of approximately USD 1.675 billion, along with up to USD 500 million in milestone-based payments, subject to customary closing conditions.

Through this acquisition, Gilead will gain access to OM336 (gamgertamig), a clinical-stage bispecific T-cell engager therapy targeting autoimmune diseases. The therapy is designed to selectively deplete harmful B cells, potentially enabling durable disease control and reducing the need for long-term immunosuppression. Early clinical studies have demonstrated promising efficacy and a differentiated safety profile in conditions such as autoimmune hemolytic anemia and immune thrombocytopenia.

The deal strengthens Gilead’s growing focus on immunology, complementing its existing portfolio in inflammation and oncology. It also reflects the company’s broader strategy to diversify beyond its core areas, including HIV and antiviral treatments, and to invest in innovative, next-generation therapies.

As part of the transaction, Gilead is also in advanced discussions with Galapagos NV for a potential strategic collaboration on the acquired assets. Under the proposed structure, Galapagos would share upfront and milestone costs, lead early development activities, and support clinical advancement, while Gilead retains global commercialization rights, excluding Greater China.

OM336 is expected to enter registrational studies by 2027, positioning it as a potential first-in-class therapy in autoimmune diseases. The asset has already received regulatory designations such as Fast Track and Orphan Drug status from the U.S. FDA, underscoring its potential clinical significance.

This acquisition highlights Gilead’s continued focus on building a robust pipeline through targeted M&A and partnerships. By adding innovative immunology assets, the company aims to address significant unmet medical needs and strengthen its long-term growth trajectory in high-value therapeutic areas.